Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 2/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15907104 | 0.92 | KDM5A (0.39) | HCAR2MEN1KMT2AHCAR3KDM5A | |
| SCHEMBL15907123 | 0.89 | MEN1 (0.35) | HCAR2MEN1KMT2AHCAR3KDM4E | |
| SCHEMBL15907093 | 0.88 | MEN1 (0.33) | PPARGPPARAMEN1KMT2A | |
| SCHEMBL15907108 | 0.86 | KDM4E (0.34) | PPARGPPARAMEN1KMT2AKDM4E | |
| SCHEMBL15907132 | 0.83 | HCAR2 (0.35) | HCAR2MEN1KMT2AHCAR3KDM4E | |
| SCHEMBL18323575 | 0.81 | PDE8A (0.36) | HCAR2MEN1KMT2AHCAR3KDM5A | |
| SCHEMBL15907115 | 0.79 | KDM5A (0.37) | KDM4EKDM5AKDM5BL3MBTL1KDM4C | |
| SCHEMBL15907105 | 0.79 | MEN1 (0.37) | HCAR2MEN1KMT2AHCAR3KDM4E | |
| SCHEMBL15907081 | 0.79 | KDM4E (0.39) | MEN1KMT2AKDM4E | |
| SCHEMBL15907101 | 0.77 | MEN1 (0.50) | HCAR2MEN1KMT2AHCAR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | PPARG 2726/4885PPARA 3596/4885HCAR2 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.